These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2005390)

  • 41. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein.
    Calvo-Calle JM; Hammer J; Sinigaglia F; Clavijo P; Moya-Castro ZR; Nardin EH
    J Immunol; 1997 Aug; 159(3):1362-73. PubMed ID: 9233633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Presence and possible role of c-ras and nuclear (c-fos and c-jun) proto-oncogene products in preimplantation embryonic development in mice.
    Ahmad K; Naz RK
    Mol Reprod Dev; 1993 Nov; 36(3):297-306. PubMed ID: 8286110
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single amino acid substitution alters T cell determinant selection during antigen processing of Staphylococcus aureus nuclease.
    Liu ZR; Williams KP; Chang YH; Smith JA
    J Immunol; 1991 Jan; 146(2):438-43. PubMed ID: 1702801
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
    Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Soluble MHC II-peptide complexes induce antigen-specific apoptosis in T cells.
    Nag B; Kendrick T; Arimilli S; Yu SC; Sriram S
    Cell Immunol; 1996 May; 170(1):25-33. PubMed ID: 8660796
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides.
    Gedde-Dahl T; Eriksen JA; Thorsby E; Gaudernack G
    Hum Immunol; 1992 Apr; 33(4):266-74. PubMed ID: 1639630
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
    Cheever MA; Chen W; Disis ML; Takahashi M; Peace DJ
    Ann N Y Acad Sci; 1993 Aug; 690():101-12. PubMed ID: 8103658
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes.
    Fenton RG; Taub DD; Kwak LW; Smith MR; Longo DL
    J Natl Cancer Inst; 1993 Aug; 85(16):1294-302. PubMed ID: 8340941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutations in residue 61 of H-Ras p21 protein influence MHC class II presentation.
    Ngo-Giang-Huong N; Kayibanda M; Deprez B; Levy JP; Guillet JG; Tilkin AF
    Int Immunol; 1995 Feb; 7(2):269-75. PubMed ID: 7734422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).
    Gedde-Dahl T; Spurkland A; Eriksen JA; Thorsby E; Gaudernack G
    Int Immunol; 1992 Nov; 4(11):1331-7. PubMed ID: 1282032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein.
    Escobar P; Yu Z; Terskikh A; Holmes N; Corradin G; Mach JP; Healy F
    Clin Exp Immunol; 1999 May; 116(2):214-9. PubMed ID: 10337009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.
    Peace DJ; Smith JW; Chen W; You SG; Cosand WL; Blake J; Cheever MA
    J Exp Med; 1994 Feb; 179(2):473-9. PubMed ID: 8294861
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MHC class I antigen expression is inversely related with tumor malignancy and ras oncogene product (p21ras) levels in human breast tumors.
    Solana R; Romero J; Alonso C; Peña J
    Invasion Metastasis; 1992; 12(3-4):210-7. PubMed ID: 1294532
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathways for activation of the ras-oncogene-encoded p21 protein.
    Pincus MR; Chung D; Dykes DC; Brandt-Rauf P; Weinstein IB; Yamaizumi Z; Nishimura S
    Ann Clin Lab Sci; 1992; 22(5):323-42. PubMed ID: 1524403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).
    Fossum B; Gedde-Dahl T; Breivik J; Eriksen JA; Spurkland A; Thorsby E; Gaudernack G
    Int J Cancer; 1994 Jan; 56(1):40-5. PubMed ID: 7903287
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins.
    Jung S; Schluesener HJ
    J Exp Med; 1991 Jan; 173(1):273-6. PubMed ID: 1670640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein.
    Peace DJ; Smith JW; Disis ML; Chen W; Cheever MA
    J Immunother Emphasis Tumor Immunol; 1993 Aug; 14(2):110-4. PubMed ID: 7506572
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro processing of insulin for recognition by murine T cells results in the generation of A chains with free CysSH.
    Hampl J; Gradehandt G; Kalbacher H; Rüde E
    J Immunol; 1992 May; 148(9):2664-71. PubMed ID: 1573264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli.
    Fenton RG; Keller CJ; Hanna N; Taub DD
    J Natl Cancer Inst; 1995 Dec; 87(24):1853-61. PubMed ID: 7494229
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation.
    Gjertsen MK; Bjorheim J; Saeterdal I; Myklebust J; Gaudernack G
    Int J Cancer; 1997 Sep; 72(5):784-90. PubMed ID: 9311595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.